Background
Introduction
The co-stimulatory inhibitor of the CD28-CD80/86-pathway, belatacept, is a promising alternative for calcineurin-inhibitors in kidney transplantation. [1] [2] [3] This co-stimulatory inhibitor does not directly down-regulate or block CD28 on T-cells, but induces T-cell anergy by depriving T-cells from the necessary co-stimulatory signal from CD80/86 on antigen-presenting cells. [4] Aggressive T cell-mediated allogeneic responses have been observed in belatacept-treated patients. [1] This phenomenon can be explained by the actions of memory T-cells that are less or not susceptible to co-stimulatory blockade of the CD28-CD80/86 pathway. [5, 6] In vitro studies demonstrated that, despite the presence of belatacept, effector-memory T-cells which lack membrane expression of CD28, i.e. CD28-negative (CD28 NULL ) T-cells, produce high levels of effector cytokines upon allogeneic stimulation. [6] [7] [8] CD28 POS T-cells can down regulate their surface CD28 when the transcriptional initiator element of CD28 is disrupted [9] , which occurs after repeated antigen-stimulation (e.g. as the result of physiological aging, chronic viral infection, malignancy, auto-immunity, and transplantation). [10] So, in belatacept-treated patients, in addition to pre-existing CD28 NULL T-cells, CD28 POS T-cells that down regulate their surface CD28 after allogeneic stimulation could also pose a threat to the renal graft. In solid organ transplantation, seemingly opposing functions of CD28 NULL T-cells have been reported. These cells can have immunoregulatory functions, [11, 12] , show features of immunoquiescence [10] , as well as mediate allogeneic or anti-viral immune responses. [5-7, 13, 14] One study reported CD4 POS CD28 NULL T-cells could play an important role in glucocorticoidresistant rejection occurring during belatacept treatment. [8] No studies on peripheral blood mononuclear cells (PBMCs) derived from end-stage renal disease (ESRD) patients have been conducted to determine the ability of their CD28 POS T-cells to down regulate surface CD28 in the presence of belatacept, making them resistant to blockade of the CD28-CD80/86-pathway. The aim of this study was to investigate a potential escape mechanism for CD28 POS T-cells under belatacept treatment, i.e. the down regulation of surface CD28 by these cells after allogeneic stimulation. PBMCs, isolated T-cell memory subsets and isolated CD28 POS T-cells were obtained from ESRD patients (one day before kidney-transplantation) and co-cultured with donor antigen in the presence or absence of belatacept to mimic allogeneic reactions in kidney transplant patients under belatacept treatment, and therefore explain the aggressive T cellmediated responses in these patients. [1] Materials and Methods
Study population and materials
Defrosted PBMCs from patients sampled one day before kidney transplantation were analyzed. gave written consent to collect their biomaterial as part of the ongoing transplant biobank programs. None of the transplant donors were from a vulnerable population and all donors or next of kin provided written informed consent that was freely given. Samples were randomly selected when enough patient and donor material were available, and when patient and donor were not identical for HLA class II. The patient characteristics are depicted in Table A in S1 File. Materials of 61 patients were used for the PBMC study (n = 33), for the isolated T-cell memory subset study (n = 4) and for the isolated CD28 POS T-cell study (n = 24). 
Flow cytometric isolation of recipients' PBMCs

Mixed lymphocyte reactions (MLRs)
The IC 50 for belatacept was determined in 6 independent MLR assays with PBMCs of healthy volunteers (Fig 1) . 
Flow cytometry
PBMCs were characterized (n = 33) before and at day 7 of the MLR. Memory subsets were defined by CCR7 and CD45RA surface expression: naïve (T N cells: CCR7+CD45RA+), centralmemory (T CM cells: CCR7+, CD45RA-), effector-memory (T EM cells: CCR7-, CD45RA-), and end-stage terminally-differentiated EMRA (T EMRA cells: CCR7-CD45RA+) T-cells. At day 7 the cells were plugged with brefeldin A (Golgiplug, BD Pharm; 1 μg/mL) for 4 hours. Thereafter, the allogeneic intracellular IFNγ-production was measured. Also the intracellular IFNγ production capacity was assessed, by re-stimulating part of the cells at day 7 with phorbolmyrisate acetate (PMA) 0.05 μg/mL and ionomycin 1 μg/mL (Sigma-Aldrich, St Louis, MO). FACSisolated memory subsets of recipient cells (n = 4 independent experiments) were stained before and after MLR using CD3 Brilliant Violet 510 (BioLegend), CD4 APC (BD), CD8 APC-Cy7 (BioLegend), CCR7 PE (BD) and CD45RO PE-Cy7 (BD). Intracellular staining was done using IFNγ Brilliant Violet 421 (BioLegend). The proportion of PKH67-FITC negative cells was assessed as measurement for proliferation. FACS-sorted CD28 POS cells (n = 24 independent Twenty independent experiments were conducted using the lower dose of belatacept (100 ng/ml) and 13 using the higher dose of belatacept (500 ng/mL). * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. 
Calculating the relative inhibition by belatacept
The relative inhibition by belatacept was expressed as the proliferation of T-cells in the presence of belatacept compared to the proliferation in the presence of IgG control, which was set to 100%:
Relative inhibition 
Statistical analyses
The differences between measurements before and after 7 days of MLR, and between IgG control and belatacept, were analyzed using the Wilcoxon signed-rank test. The differences between belatacept 100 ng/mL and belatacept 500 ng/mL were analyzed using the Mann-Whitney-U test. Graph pad prism 5.01 (GraphPad Software, San Diego, CA) was used for statistical analyses. P-values with a 2-sided α of 0.05 were considered statistically significant. When not otherwise specified, medians [range] are presented.
Results
Despite the dose-dependent inhibition by belatacept of T-cell proliferation, residual T-cell proliferation was still present when high doses of belatacept were added Belatacept inhibited T-cell proliferation in a dose-dependent manner (Fig 1) . The IC 50 of belatacept for T-cell proliferation was 215 ng/mL [CI95% 123-376 ng/mL) in MLRs of healthy volunteers' PBMCs. Remarkably, even at very high concentrations, belatacept could not inhibit Tcell proliferation more than ±70%, resulting in a residual proliferation of ±30%.
A concentration lower and a concentration higher than the IC50of belatacept were used in further experiments (100 ng/mL and 500 ng/mL), to ensure the inhibitory effects of belatacept were dose-dependent.
In MLRs of PBMCs of ESRD patients stimulated with allo-antigen, both CD4 POS and CD8 POS T-cells were significantly inhibited in proliferation by the lower and higher dose of belatacept, in a dose-dependent manner (Fig 1C) Predominance of effector-memory T-cells after allogeneic stimulation was enhanced by belatacept
The T-cells that proliferated upon allogeneic stimulation were analyzed in the presence and absence of belatacept to gain more insight into the alloreactive T-cells that were less susceptible to belatacept (Fig 2A) . A predominance of effector-memory T-cells was seen within the proliferated CD4 POS and CD8 POS T-cells after allo-antigen stimulation in the presence of the higher dose of belatacept (500 ng/mL 
Phenotyping and function of alloreactive effector-memory T-cells
Since the allo-reactive proliferated T-cells mostly consisted of effector-memory T-cells, these cells were further analyzed for CD28-expression and allogeneic IFNγ-production (Fig 3) . The proliferated effector-memory T-cells were compared to the total effector-memory T-cell population (both proliferated and non-proliferated cells Isolated effector-memory T cells were not inhibited in differentiation or IFNγ production by belatacept
For detailed information regarding the experiments using isolated memory subsets, see Table B in S1 File. Sufficient cell numbers were not available for all test conditions. The differentiation of isolated effector-memory T-cells into central-memory or end-stage differentiated effector-memory T-cells was not inhibited by belatacept 500 ng/mL (Fig 4A and Table D in S1 File). The proliferation within the newly formed memory subsets, however, was high and not inhibited by belatacept, especially in the newly formed effector-memory and T EMRA cells (Fig  4B and Table D in S1 File). Intracellular IFNγ concentrations were highest in the newly formed memory subsets differentiated from isolated naïve, effector-memory and T EMRA cells (Table E in S1 File). Belatacept 500 ng/mL could not prevent the IFNγ production by these induced subsets Twenty independent experiments were conducted using the lower dose of belatacept (100 ng/ml) and 13 using the higher dose of belatacept (500 ng/mL). * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0. (Table E in S1 File). IFNγ production by isolated effector-memory T-cells was also not blocked by belatacept (Fig 4C and Table E in S1 File). Belatacept could, however, inhibit IFNγ production by the isolated naïve and central-memory T-cells (S2C Fig), as well as in the newly formed subsets differentiated from central-memory T-cells (Table E in S1 File).
The indirect target of belatacept, CD28, can be down-regulated by Tcells upon allogeneic stimulation, resulting in IFNγ-producing CD28 NULL
T-cells
To study the dynamics of CD28-expression on T-cells, pure CD28
POS and CD28 NULL cell populations were studied after allogeneic stimulation (Fig 5) . A fair proportion of the isolated 
effector-memory T-cells and their CD28 expression and the intracellular IFNγ production (A). The percentage of CD28
POS effector-memory T-cells, (B) and the percentage of IFNγ producing cells (C) was assessed in the total and in the proliferated effector-memory CD4 POS and CD8 POS populations upon 7-day allogeneic stimulation by means of MLR. The percentages are given in the presence of human IgG control, 100 ng/mL or 500 ng/mL belatacept. N.B.: Black lines represent the medians. The upper and lower borders of the boxes represent the 10 th and 90 th percentile. The error lines represent the minimal and maximal value within 1.5 quartile distances of the box. Values above 1.5 quartile distances of the box are considered outliers and represented are by a dot. Twenty samples were used for the lower dose of belatacept (100 ng/ml) and 13 samples for the higher dose of belatacept (500 ng/mL). * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. 
CD28
NULL T-cells up-regulated CD28, but more importantly, also a proportion of the CD28 POS T-cells down-regulated CD28. (Fig 5A and 5B ) Therefore, CD28-expression was also studied within proliferated isolated CD28 POS T-cells, in the presence or absence of belatacept (Fig 5C) . The inhibitory effect on isolated CD28 POS T-cell proliferation is depicted in S3 Fig. After allogeneic stimulation, in the presence of belatacept 100 ng/mL, 6% [1-49%] of the CD4 POS T-cells did not express CD28 anymore and 5% [1-53%]of the CD8 POS population.
These percentages were similar to the percentages of CD28 NULL T-cells in the absence of belatacept (Fig 5D) . Similar proportions of CD28 NULL T-cells were found for cultures with the higher concentration of belatacept. The allogeneic IFNγ production was compared between T-cells that remained CD28 POS and T-cells that had down-regulated their CD28 surface molecules (Fig 5C for typical examples) . In the presence of 100 ng/mL belatacept, the proportion of CD4 POS CD28 NULL T-cells that produced IFNγ (39% [4-93%] ) was comparable to cells that remained CD28 POS (15% [2-68%]), p = 0.08. (Fig 5E) The same was seen when 500 ng/mL belatacept was added. Within the CD8 POS T-cells, in the presence of 100 ng/mL belatacept, slightly more CD28 POS T-cells produced IFNγ than the cells that turned CD28 NULL : 7%[0-96%] vs. 4% [0-66%], respectively, p = 0.003. This difference was not observed when 500 ng/mL belatacept was added to the cultures. Similar percentages of IFN-γ production were found for the IgG control samples, i.e. in the absence of belatacept. (Fig 5E) 
Discussion
Here, the ability of ESRD patients' CD28
POS T-cells to down-regulate surface CD28 upon allogeneic stimulation was studied after belatacept was added ex vivo. Kidney transplantation was mimicked to explain the severe T-cell-mediated immune responses that have been observed in belatacept-treated patients. [1] Although the overall allogeneic proliferation by T-cells was inhibited by belatacept, this inhibition never reached 100% (Fig 1) . Moreover, a part of the antigen-reactive T-cells down-regulated surface CD28 molecules without becoming anergic (i.e. their capacity to produce intracellular IFNy production upon allogeneic stimulation remained intact; Fig 5E) . Even in the presence of belatacept, the co-stimulatory inhibitor of the CD80/86-CD28 pathway, these originally CD28 POS T-cellswere not susceptible to co-stimulatory blockade and are therefore a selection of the most dangerous immune cells for the allograft. [6, 7] In addition, amongst the antigen-reactive proliferated T-cells, a large proportion remained CD28 POS and also produced intracellular IFNγ. Explanations for the severe alloreactivity in belatacept-treated patients include the possibility that belatacept inhibits negative regulators of the immune system [15, 16] ; ineffectively permeate lymph nodes and kidney tissue [17] ; or the alloreactivity is the result of heterologous immunity, like EBV positive memory T cells may cross-react with donor HLA expressed on the transplanted kidney. [18] Based on our research presented here, we postulate three additional mechanisms for the severe alloreactivity in belatacept-treated patients [1] : (i) proliferation is not inhibited in all T-cells; (ii) naïve and central-memory T-cells differentiate into effector-memory T-cells, which are less susceptible to immunosuppressive drugs [19, 20] ; and (iii) T-cells can down-regulate their cell surface CD28 molecule and consequently become independent of co-stimulatory signals from CD80/86. POS T-cells (A) and FACS-sorted CD28 NULL T-cells (B) from n = 16 kidney-transplant candidates were stimulated for 7 days with allo-antigen (purities !95%). CD28-expression was assessed after 7 days of MLR and compared to the CD28-expression of the pure starting populations. Gating strategies to determine proliferated CD4 POS and CD8 POS T-cells are depicted, as well as a typical example for proliferation with and without belatacept (CD). The gating strategy for CD28 expression within proliferated CD4 POS and CD8 POS T-cells, including allogeneic IFNγ production, is depicted in a typical example (C). IFNγ expression is depicted in this typical example in the presence of 100 ng/mL belatacept. The proportion of CD4 POS and CD8 The log [inhibitor]-versus-response curve of belatacept (Fig 1B) demonstrated that a plateau phase is reached for its inhibitory capacity. Even when high doses of belatacept (>1 mg/ mL) were added in vitro, the maximum inhibition was ±70%. In the BENEFIT study, serum belatacept concentrations were not higher than 10 μg/mL [1, 21] , suggesting that T-cell proliferation may also be incompletely blocked in vivo. The IC 50 of belatacept found in our in vitro experiments (0.22 μg/mL, 95% CI 0.12-0.38 μg/mL) was similar to the serum belatacept concentrations of stable patients 2-5 years after kidney transplantation that received belatacept every 8 weeks (0.13-0.21 μg/mL). [2] Because the volume of distribution of belatacept is low [22] , the concentration in lymph nodes or graft tissue is presumably even lower, which could result in even more proliferation of allo-reactive T-cells.
It is known that CD28 NULL T-cells are not susceptible to belatacept and can produce high amounts of effector cytokines. [5] [6] [7] When adding belatacept to patients' PBMCs ex vivo, a smaller proportion of CD28 POS T-cells, thus a larger proportion of CD28 NULL T-cells was observed within the cells proliferated upon allogeneic stimulation ( Figs 3B and 5D ). This can be explained by a selection of CD28 NULL T-cells, because these cells are not susceptible to belatacept. Another explanation is that not all CD28 POS T-cells are inhibited by belatacept and that their CD28 co-stimulatory molecule is down-regulated, since CD28 NULL T-cells were present in cultures of isolated CD28 POS T-cells after one week of MLR. (Fig 5A and 5D ) When adding the higher dose of belatacept to MLRs with patients' PBMCs (Fig 3) , the predominance of , which means that despite their surface CD28 molecules these cells were not susceptible for belatacept.
To accurately establish the dynamics of CD28-expression by alloreactive T-cells of ESRD patients in the presence of belatacept, the proportion of CD28 NULL T-cells was measured after one week of allogeneic stimulated pure CD28 POS T-cells. (Fig 5) Indeed, even in the presence of belatacept, a proportion of T-cells lost their CD28 surface molecules upon allogeneic stimulation, making them not susceptible to inhibition of the CD28-pathway. These CD28 NULL Tcells did not become senescent anergic, since they remained capable of producing intracellular IFNγ upon allogeneic stimulation. For CD4 POS and CD8 POS T-cells, both CD28 POS or newlyformed CD28 NULL T-cells produced comparable large amounts of allogeneic IFNγ (Fig 5E) .
The differentiation of CD28 POS T-cells into IFNγ-producing CD28 NULL T-cells reflects the absence of belatacept-induced anergy of these T-cells (Fig 5) , possibly because of alternative routes for co-stimulation. [23] In the present study, using PBMCs of kidney transplant candidates, the alloreactive cells mostly had effector-memory T-cell features, especially after allogeneic stimulation in the presence of belatacept (Fig 2) . However, the absolute number of such responding cells were lower because belatacept inhibits T-cell proliferation (Fig 1) . The predominance of effectormemory T cells is in line with previous findings from studies using animals [5] or PBMCs from healthy volunteers. [6, 7] These effector memory T-cells are less susceptible to the currently prescribed immunosuppressive drugs, like tacrolimus [19] , and are especially less subject to coquartile distances of the box. Values above 1.5 quartile distances of the box are considered outliers and are represented by a dot. Levels of significance in (B) were given for the difference between proliferation in the presence of belatacept and the IgG control. * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001, T N = naïve T-cells, T CM = central-memory T-cells, T EM = effector-memory T-cells, T EMRA = terminally differentiated EMRA T-cells. doi:10.1371/journal.pone.0148604.g005 stimulation blockade. [23] The predominance of effector-memory T-cells could be the result of less affected proliferation of the pre-existing effector-memory T-cells. Isolated effector-memory T cells could, however, be inhibited in proliferation by belatacept (Fig 4B and Table D in S1 File), but not in differentiation into central-memory and T EMRA T cells or in IFNγ production (Fig 4B, Tables C and E in S1 File). The selection of effector-memory T-cells was evident when the higher dose of belatacept was added, since naïve and central-memory T-cells are then more sufficiently inhibited (Figs 1 and 2 ). In addition, the predominance of effector-memory T-cells could also be the result of differentiation of naïve and central-memory T-cells into the effectormemory phenotype upon allogeneic stimulation ( S2 Fig) . [24] A limitation of our study is the low availability of patient materials, which makes it difficult to test multiple conditions, e.g. the distinction between allorecognition via the direct or indirect pathway. Also, the difference between patients and healthy controls would be an interesting question, but does not address to our initial study purpose.
In conclusion, CD28-positive, mostly effector-memory T-cells can become resistant to belatacept by down-regulating their surface CD28 molecules, indicating differentiation into highly allo-reactive CD28 NULL T-cells. This study provides evidence that not only CD28 NULL T-cells but also CD28 POS T-cells can mediate anti-donor responses despite belatacept treatment.
Supporting Information Table B -E in S1 File. The differentiation of isolated T-cell memory subsets (naïve, centralmemory and end-stage terminally-differentiated effector-memory T-cells) into other memory subsets is depicted in the presence and absence of 500 ng/mL belatacept (A). All starting population were !97% pure. The proliferation of these isolated memory subsets was assessed in the presence and absence of 500 ng/mL belatacept (B), as well as the allogeneic IFNγ production (C). bela = belatacept 500 ng/mL, T Table B : Detailed information about the experiments using isolated T-cell memory subsets. Table C : Differentiation by isolated T-cell memory subsets upon allo-antigen stimulation. Table D: Proliferation by isolated T-cell memory subsets upon allo-antigen stimulation. 
